🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Clinical Study of Single Incision Laparoscopic Cholecystectomy in the Treatment of Patients With Acute Cholecystitis

RecruitingNAAges 18 Years - 70 YearsAllSecond Affiliated Hospital, Zhejiang University, …
NCT06074679 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Gallstone is a common disease in China.At present, the prevalence of gallstones in China is 15 %, and about 210 million people are sick. Acute cholecystitis is acute gallbladder inflammation, is one of the main complications of cholelithiasis or gallstones. The removal of gallbladder and gallstones in patients with acute cholecystitis in the presence of biliary pain will prevent the recurrence of gallbladder and reduce the risk of cholecystitis progression. If gallbladder perforation is not treated in time, the mortality rate is 30 %. Acute acalculous cholecystitis without treatment will be life-threatening, with a mortality rate of up to 50 %. At present, the vast majority of patients with acute cholecystitis are treated with 4-hole traditional laparoscopic cholecystectomy and open cholecystectomy. Their postoperative quality of life, pain and scar-related complications, remain major fa

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Acute cholecystitis（GradeⅠ，II） Exclusion Criteria: * Combined with liver cirrhosis (Child grade B and above) * Upper abdominal surgical history; * Changes in surgical plan (conversion to laparotomy,cholangiography, bile duct exploration, bile duct injury repair, abscess clearance, multivisceral resection.) * Patients and their families do not agree with the treatment lost follow-up
💊

What it tests

  • Open cholecystectomy
📍

Where

5 sites
Shexian Branch, Second Affiliated Hospital, School of Medicine, Zhejiang University
Huangshan City, China
2nd Affiliated Hospital, School of Medicine, Zhejiang University, China
Hangzhou, China
Changxing Branch, Second Affiliated Hospital, School of Medicine, Zhejiang University
Huzhou, China
Suichang Branch, Second Affiliated Hospital, School of Medicine, Zhejiang University
Lishui, China
Jiande Branch, Second Affiliated Hospital, School of Medicine, Zhejiang University
Meicheng, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy